tbuckley/cabot-search huggingface dataset:
Minimal Residual Disease in Patients With Nonmetastatic Triple-Negative Breast Cancer
Authors: Andrew A. Davis, Massimo Cristofanilli
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Comparing Needles and Methods of Endoscopic Ultrasound–Guided Fine-Needle Biopsy to Optimize Specimen Quality and Diagnostic Accuracy for Patients With Pancreatic Masses in a Randomized Trial
Authors: Ji Young Bang, Konrad Krall, Nirag Jhala, Charanjeet Singh, Mohamedtaki Tejani, Juan Pablo Arnoletti, Udayakumar Navaneethan, Robert Hawes, Shyam Varadarajulu
Journal: Clinical Gastroenterology and Hepatology (2020)
P-171 Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet REFLECT trial inclusion criteria
Authors: T. Sho, G. Suda, K. Ogawa, T. Kitagataya, R. Yamada, T. Shigesawa, K. Suzuki, A. Nakamura, M. Nakai, M. Natsuizaka, K. Morikawa, N. Sakamoto
Journal: Annals of Oncology (2020)
P-23 Microwave ablation versus radiofrequency ablation in BCLC-A hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials
Authors: A. Rizzo, A. Ricci, S. Tavolari, C. Felicani, A. Palloni, G. Frega, S. De Lorenzo, M. Deserti, F. Vasuri, M. Nigro, F. Abbati, A. Di Federico, M. Mosca, V. Mollica, I. Maggio, M. Salati, M. Di Marco, F. Tovoli, M. Cescon, A. Pinna, C. Serra, G. Brandi
Journal: Annals of Oncology (2020)
Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation
Authors: Stefan O. Ciurea, Doris Soebbing, Gabriela Rondon, Kai Cao, Gheath Alatrash, Sairah Ahmed, Uday Popat, Betul Oran, Qaiser Bashir, Partow Kebriaei, Indreshpal Kaur, Katayoun Rezvani, Elizabeth J Shpall, Dean Anthony Lee, Richard E. Champlin
Journal: Blood (2017)
Extracellular ATP and CD39 Activate cAMP-Mediated Mitochondrial Stress Response to Promote Cytarabine Resistance in Acute Myeloid Leukemia
Authors: Nesrine Aroua, Emeline Boet, Margherita Ghisi, Marie-Laure Nicolau-Travers, Estelle Saland, Ryan Gwilliam, Fabienne de Toni, Mohsen Hosseini, Pierre-Luc Mouchel, Thomas Farge, Claudie Bosc, Lucille Stuani, Marie Sabatier, Fetta Mazed, Clément Larrue, Latifa Jarrou, Sarah Gandarillas, Massimiliano Bardotti, Muriel Picard, Charlotte Syrykh, Camille Laurent, Mathilde Gotanègre, Nathalie Bonnefoy, Floriant Bellvert, Jean-Charles Portais, Nathalie Nicot, Francisco Azuaje, Tony Kaoma, Carine Joffre, Jérome Tamburini, Christian Récher, François Vergez, Jean-Emmanuel Sarry
Journal: Cancer Discovery (2020)

Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine-resistant leukemic cells from both AML cell lines and patient samples in vivo and in vitro. CD39 cell-surface expression and activity is increased in patients with AML upon chemotherapy compared with diagnosis, and enrichment in CD39-expressing blasts is a marker of adverse prognosis in the clinics. High CD39 activity promotes cytarabine resistance by enhancing mitochondrial activity and biogenesis through activation of a cAMP-mediated adaptive mitochondrial stress response. Finally, genetic and pharmacologic inhibition of CD39 ecto-ATPase activity blocks the mitochondrial reprogramming triggered by cytarabine treatment and markedly enhances its cytotoxicity in AML cells in vitro and in vivo. Together, these results reveal CD39 as a new residual disease marker and a promising therapeutic target to improve chemotherapy response in AML. SIGNIFICANCE: Extracellular ATP and CD39-P2RY13-cAMP-OxPHOS axis are key regulators of cytarabine resistance, offering a new promising therapeutic strategy in AML.This article is highlighted in the In This Issue feature, p. 1426.
Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis
Authors: Moshe Talpaz, Jean-Jacques Kiladjian
Journal: Leukemia (2020)

Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival. Constitutive activation of the janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway in MF leads to cell proliferation, inhibition of cell death, and clonal expansion of myeloproliferative malignant cells. Fedratinib is a selective oral JAK2 inhibitor recently approved in the United States for treatment of adult patients with intermediate-2 or high-risk MF. In mouse models of JAK2V617F-driven myeloproliferative disease, fedratinib blocked phosphorylation of STAT5, increased survival, and improved MF-associated disease features, including reduction of white blood cell counts, hematocrit, splenomegaly, and fibrosis. Fedratinib exerts off-target inhibitory activity against bromodomain-containing protein 4 (BRD4); combination JAK/STAT and BRD4 inhibition was shown to synergistically block NF-kB hyperactivation and inflammatory cytokine production, attenuating disease burden and reversing bone marrow fibrosis in animal models of MPNs. In patients, fedratinib is rapidly absorbed and dosed once daily (effective half-life 41 h). Fedratinib showed robust clinical activity in JAK-inhibitor-naïve patients and in patients with MF who were relapsed, refractory, or intolerant to prior ruxolitinib therapy. Fedratinib is effective regardless of JAK2 mutation status. Onset of spleen and symptom responses are typically seen within the first 1-2 months of treatment. The most common adverse events (AEs) with fedratinib are grades 1-2 gastrointestinal events, which are most frequent during early treatment and decrease over time. Treatment discontinuation due to hematologic AEs in clinical trials was uncommon (~3%). Suspected cases of Wernicke's encephalopathy were reported during fedratinib trials in ~1% of patients; thiamine levels should be monitored before and during fedratinib treatment as medically indicated. Phase III trials are ongoing to assess fedratinib effects on long-term safety, efficacy, and overall survival. The recent approval of fedratinib provides a much-needed addition to the limited therapeutic options available for patients with MF.
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Authors: Laura Reyes-Uribe, Wenhui Wu, Ozkan Gelincik, Prashant V Bommi, Alejandro Francisco-Cruz, Luisa M Solis, Patrick M Lynch, Ramona Lim, Elena M Stoffel, Priyanka Kanth, N Jewel Samadder, Maureen E Mork, Melissa W Taggart, Ginger L Milne, Lawrence J Marnett, Lana Vornik, Diane D Liu, Maria Revuelta, Kyle Chang, Y Nancy You, Levy Kopelovich, Ignacio I Wistuba, J Jack Lee, Shizuko Sei, Robert H Shoemaker, Eva Szabo, Ellen Richmond, Asad Umar, Marjorie Perloff, Powel H Brown, Steven M Lipkin, Eduardo Vilar
Journal: Gut (2020)

Patients with Lynch syndrome (LS) are at markedly increased risk for colorectal cancer. It is being increasingly recognised that the immune system plays an essential role in LS tumour development, thus making an ideal target for cancer prevention. Our objective was to evaluate the safety, assess the activity and discover novel molecular pathways involved in the activity of naproxen as primary and secondary chemoprevention in patients with LS.
Reply to T.J.A. Dekker
Authors: Shanu Modi, Haeseong Park, Rashmi K. Murthy, Hiroji Iwata, Kenji Tamura, Junji Tsurutani, Alvaro Moreno-Aspitia, Toshihiko Doi, Yasuaki Sagara, Charles Redfern, Ian E. Krop, Caleb Lee, Yoshihiko Fujisaki, Masahiro Sugihara, Lin Zhang, Javad Shahidi, Shunji Takahashi
Journal: Journal of Clinical Oncology (2020)
Galectin 3 Protein Network Analysis By Reverse Protein Arrays Demonstrates Regulation of MCL-1, PKC Delta and CD74 Associated with Poor Survival in Patients with AML
Authors: Peter P. Ruvolo, Chenyue Hu, Yihua Qiu, Vivian Ruvolo, Kevin R Coombes, Amina Qutub, Michael Andreeff, Steven Kornblau
Journal: Blood (2017)
P-111 Prognostic value of inflammation-based scores for patients treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Authors: K. Harada, S. Nakano, R. Saito, K. Ito, Y. Kawamoto, H. Nakatsumi, S. Yuki, N. Sakamoto, Y. Komatsu
Journal: Annals of Oncology (2020)
The Estimation Formula for the Urinary Albumin-Creatinine Ratio Based on the Protein-Creatinine Ratio Are Not Valid for a Kidney Transplant and a Living Donor Cohort
Authors: Ulrich Jehn, Dennis Görlich, Stefan Reuter
Journal: Journal of the American Society of Nephrology (2020)

Weaver et al. [1][1] recently described equations for estimating the median urinary albumin-to-creatinine ratio (ACR) from the protein-to-creatinine ratio (PCR) on the basis of median regression models for log ACR in a Canadian population–based cohort. Patients with kidney transplants (KTx) were
Elucidating Durable Responses to Immune Checkpoint Inhibition
Authors: Pasquale Rescigno, Caterina Aversa, Mateus Crespo, George Seed, Maryou Lambros, Bora Gurel, Ines Figueiredo, Diletta Bianchini, Ruth Riisnaes, Rita Pereira, Maria D. Fenor de la Maza, Juliet Carmichael, Khobe Chandran, Ana Ferreira, Claudia Bertan, Alec Paschalis, Andra Curcean, Adam Sharp, Wei Yuan, Nina Tunariu, Christian Poehlein, Suzanne Carreira, Johann S. de Bono
Journal: European Urology (2020)
P-317 Survival outcomes among patients with locally advanced esophageal cancer treated within a multidisciplinary gastro-esophageal cancer functional unit
Authors: A. Plaja Salarich, A. Ferrando Díez, C. Bugés Sánchez, C. Hierro Carbó, M. Caro Gallarín, M. Viciano Martín, S. España Fernández, O. García Calduch, E. Barluenga Torres, J. Colan Hernández, R. López Martos, M. Sendra Gonzalez, M. Álvaro Pardo, C. Joaquin Ortiz, M. Riquelme Olivares, A. Hernandez Marfil, N. Calderon Ruiz, M. López Cuellar, M. José Osuna, L. Layos Romero, J. Manzano Mozo, A. Font Pous
Journal: Annals of Oncology (2020)
P-312 Perioperative chemotherapy versus surgery alone on resectable advanced gastric cancer in a Moroccan population
Authors: S. Lalaoui Rachidi, N. Benhima, K. Lakloumi, K. El Bouaouidi, M. Kaakoua, H. Jouihri, S. El Ouarzazi, M. Layachi, M. El Fadli, I. Essadi, R. Belbaraka
Journal: Annals of Oncology (2020)
P-345 Evaluation of a fully automated Idylla test system for microsatellite instability in a cohort of Spanish patients with colorectal carcinoma in a single institution
Authors: L. Carnerero Córdoba, M. Perez García, A. Segura Perez, I. García Perez, M. Gutierrez Ariza, B. González-Astorga
Journal: Annals of Oncology (2020)
Cell Lineage-Based Stratification for Glioblastoma
Authors: Zilai Wang, Daochun Sun, Yu-Jung Chen, Xuanhua Xie, Yufeng Shi, Viviane Tabar, Cameron W. Brennan, Tejus A. Bale, Chenura D. Jayewickreme, Dan R. Laks, Sheila Alcantara Llaguno, Luis F. Parada
Journal: Cancer Cell (2020)
Characteristics of Specialist‐Diagnosed Asthma‐COPD Overlap in Severe Asthma: Observations from the Korean Severe Asthma Registry (KoSAR)
Authors: Hyun Lee, Sang‐Heon Kim, Byung‐Keun Kim, Youngsoo Lee, Hwa Young Lee, Ga‐Young Ban, Min‐Hye Kim, Joo‐Hee Kim, Jae‐Woo Kwon, So‐Young Park, Jae‐Woo Jung, So Young Park, Chan Sun Park, Chin Kook Rhee, Taehoon Lee, Jae‐Hyun Lee, So Ri Kim, Jong‐Sook Park, Heung‐Woo Park, Kwang Ha Yoo, Yeon‐Mok Oh, Young‐Il Koh, Byung‐Jae Lee, An‐Soo Jang, Sang‐Heon Cho, Hae‐Sim Park, Choon‐Sik Park, You Sook Cho, Ho Joo Yoon
Journal: Allergy (2020)

Abstract Background While the clinical characteristics and outcomes of asthma‐chronic obstructive pulmonary disease (COPD) overlap (ACO) have been frequently compared with those of COPD or asthma, the prevalence and features of ACO in patients with severe asthma are unclear. Objectives Evaluation of the prevalence and clinical features of ACO using the Korean severe asthma registry. Methods At the time of registration, ACO was determined in patients with severe asthma by attending specialists. Patients were classified into ACO and non‐ACO groups, and the demographic and clinical characteristics of these two groups were compared. Results Of 482 patients with severe asthma, 23.7% had ACO. Patients in the ACO group were more likely to be male ( P &lt; .001), older ( P &lt; .001), and ex‐ or current smokers ( P &lt; .001) compared with those in the non‐ACO group. Patients in the ACO group had lower mean forced expiratory volume in 1 second ( P &lt; .001) and blood eosinophil percentage ( P = .006), but higher blood neutrophil percentage ( P = .027) than those in the non‐ACO group. The ACO group used more inhaled long‐acting muscarinic antagonist ( P &lt; .001), methylxanthine ( P = .001), or sustained systemic corticosteroid ( P = .002). In addition, unscheduled emergency department visits due to exacerbation were more frequent in the ACO group ( P = .006). Conclusion Among patients with severe asthma, those with ACO were older, predominantly male, and were more likely to have a smoking history than those with asthma only. Patients with ACO used more systemic corticosteroid and had more frequent exacerbations related to emergency department visits than those with severe asthma only.
Glucose-6-Phosphate Dehydrogenase Is Not Essential for K-Ras–Driven Tumor Growth or Metastasis
Authors: Jonathan M. Ghergurovich, Mark Esposito, Zihong Chen, Joshua Z. Wang, Vrushank Bhatt, Taijin Lan, Eileen White, Yibin Kang, Jessie Yanxiang Guo, Joshua D. Rabinowitz
Journal: Cancer Research (2020)

The enzyme glucose-6-phosphate dehydrogenase (G6PD) is a major contributor to NADPH production and redox homeostasis and its expression is upregulated and correlated with negative patient outcomes in multiple human cancer types. Despite these associations, whether G6PD is essential for tumor initiation, growth, or metastasis remains unclear. Here, we employ modern genetic tools to evaluate the role of G6PD in lung, breast, and colon cancer driven by oncogenic K-Ras. Human HCT116 colorectal cancer cells lacking G6PD exhibited metabolic indicators of oxidative stress, but developed into subcutaneous xenografts with growth comparable with that of wild-type controls. In a genetically engineered mouse model of non-small cell lung cancer driven by K-Ras G12D and p53 deficiency, G6PD knockout did not block formation or proliferation of primary lung tumors. In MDA-MB-231-derived human triple-negative breast cancer cells implanted as orthotopic xenografts, loss of G6PD modestly decreased primary site growth without ablating spontaneous metastasis to the lung and moderately impaired the ability of breast cancer cells to colonize the lung when delivered via tail vein injection. Thus, in the studied K-Ras tumor models, G6PD was not strictly essential for tumorigenesis and at most modestly promoted disease progression. SIGNIFICANCE: K-Ras-driven tumors can grow and metastasize even in the absence of the oxidative pentose pathway, a main NADPH production route.
Rhinovirus Infections in Individuals with Asthma Increase ACE2 Expression and Cytokine Pathways Implicated in COVID-19
Authors: Eugene H. Chang, Amanda L. Willis, Casey E. Romanoski, Darren A. Cusanovich, Nima Pouladi, Jianrong Li, Yves A. Lussier, Fernando D. Martinez
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Time to go back to school: several good reasons beyond low infection risk
Authors: Federico Marchetti, Giorgio Tamburlini
Journal: BMJ (2020)

Low risk of contagion of covid-19 infection among children is one reason for the prompt reopening of schools.1 There are, however, several other good reasons to be considered.

Firstly, prolonged closure yields serious consequences for all children and particularly for those already living in difficult circumstances.2 With over 90% of students worldwide out of the educational setting, the …
O-21 METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites
Authors: Y. Kagawa, E. Elez Fernandez, J. Garcia-Foncillas, H. Bando, H. Taniguchi, A. Vivancos, K. Akagi, A. Garcia, T. Denda, J. Ros, T. Nishina, I. Baraibar, Y. Komatsu, D. Ciardiello, E. Oki, T. Satoh, T. Kato, T. Yamanaka, J. Tabernero, T. Yoshino
Journal: Annals of Oncology (2020)
3D printing‐based drug-loaded implanted prosthesis to prevent breast cancer recurrence post‐conserving surgery
Authors: Wenyan Hao, Zengjuan Zheng, Lin Zhu, Lulu Pang, Jinqiu Ma, Siqing Zhu, Lina Du, Yiguang Jin
Journal: Asian Journal of Pharmaceutical Sciences (2020)

Systemic chemotherapy of breast cancer is commonly delivered as a large dose and has toxic side effects. Local chemotherapy would overcome the shortcomings of systemic reconstruction and could play an important role in breast cancer surgery according to personalized demand. The application of three-dimensional (3D) printing technology makes personalized customization possible. We designed and prepared a prosthesis containing paclitaxel (PTX) and doxorubicin (DOX) microspheres (PPDM) based on 3D printing to prevent tumor recurrence and metastasis after breast conserving surgery. Polydimethysiloxane has good biocompatibility and was used as a drug carrier in this study. The average particle size of the PTX and DOX microspheres were approximately 3.1 µm and 2.2 µm, respectively. The drug loading of PTX and DOX microspheres was 4.2% and 2.1%, respectively. In vitro drug release studies demonstrated that the 3D-printed prosthesis loaded with PTX and DOX microspheres could release the drugs continuously for more than 3 weeks and thereby suppress cancer recurrence with reduced side effects. The PTX and DOX microspheres not only exerted a synergistic effect, but also achieved a good sustained release effect. In vivo evaluation showed that the PPDM could effectively inhibit breast cancer recurrence and metastasis in mice with breast cancer. PPDM are expected to achieve postoperative chemotherapy for breast cancer and be highly efficient to prevent local breast cancer recurrence and metastasis.
Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence
Authors: Bon San Koo, Ji Seon Oh, Seo Young Park, Ji Hui Shin, Ga Young Ahn, Seunghun Lee, Kyung Bin Joo, Tae-Hwan Kim
Journal: Annals of the Rheumatic Diseases (2020)

Tumour necrosis factor inhibitors (TNFis) have been suggested to slow radiographic progression in patients with ankylosing spondylitis. However, limitations such as variations in disease activity, complex drug administration and short follow-up duration make it difficult to determine the effect of TNFis on radiographic progression. The aim of the study was to investigate whether long-term treatment with TNFis can reduce radiographic progression in patients with ankylosing spondylitis using 18-year longitudinal real-world data.This retrospective study was conducted between January 2001 and December 2018 at a single centre. Among the 1280 patients whose electronic medical records were reviewed, data of 595 patients exposed to TNFis at least once were included. Among them, time intervals of TNFi exposure or non-exposure were determined in 338 patients ('on the TNFis' or 'off the TNFis' intervals, respectively). The difference in the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) change rate between 'on the TNFis' and 'off the TNFis' intervals was investigated.We obtained 2364 intervals of 338 patients (1281 'on the TNFis' and 1083 'off the TNFis' intervals). In the marginal structural model for inverse probability of treatment weighting, the change rate of mSASSS significantly decreased with the use of TNFis (β=-0.112, p=0.004), and the adjusted mSASSS changes were 0.848 and 0.960 per year during 'on the TNFis' and 'off the TNFis' intervals, respectively.Compared with treatment without TNFis, treatment with TNFis slowed radiologic progression significantly.
Longitudinal Cytokine Profiling Identifies GRO‐α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia
Authors: Nina F. Øbro, Jacob Grinfeld, Miriam Belmonte, Melissa Irvine, Mairi S. Shepherd, Tata Nageswara Rao, Axel Karow, Lisa M. Riedel, Oliva B. Harris, E. Joanna Baxter, Jyoti Nangalia, Anna Godfrey, Claire N. Harrison, Juan Li, Radek C. Skoda, Peter J. Campbell, Anthony R. Green, David G. Kent
Journal: HemaSphere (2020)

Supplemental Digital Content is available in the text
The Australian Institute of Sport (AIS) and National Eating Disorders Collaboration (NEDC) position statement on disordered eating in high performance sport
Authors: Kimberley R Wells, Nikki A Jeacocke, Renee Appaneal, Hilary D Smith, Nicole Vlahovich, Louise M Burke, David Hughes
Journal: British Journal of Sports Medicine (2020)

Identification, evaluation and management of disordered eating (DE) is complex. DE exists along the spectrum from optimised nutrition through to clinical eating disorders (EDs). Individual athletes can move back and forth along the spectrum of eating behaviour at any point in time over their career and within different stages of a training cycle. Athletes are more likely to present with DE than a clinical ED. Overall, there is a higher prevalence of DE and EDs in athletes compared with non-athletes. Additionally, athletes participating in aesthetic, gravitational and weight-class sports are at higher risk of DE and EDs than those in sports without these characteristics. The evaluation and management of DE requires a cohesive team of professional practitioners consisting of, at minimum, a doctor, a sports dietitian and a psychologist, termed within this statement as the core multidisciplinary team. The Australian Institute of Sport and the National Eating Disorders Collaboration have collaborated to provide this position statement, containing guidelines for athletes, coaches, support staff, clinicians and sporting organisations. The guidelines support the prevention and early identification of DE, and promote timely intervention to optimise nutrition for performance in a safe, supported, purposeful and individualised manner. This position statement is a call to action to all involved in sport to be aware of poor self-image and poor body image among athletes. The practical recommendations should guide the clinical management of DE in high performance sport.